Laboratory Interpretation and Management
The mildly elevated total bilirubin (1.6 mg/dL) is most likely a spurious laboratory artifact caused by naproxen interference with the bilirubin assay, not true liver injury, and requires no intervention beyond monitoring if the patient remains asymptomatic. 1
Key Laboratory Findings Analysis
Bilirubin Elevation - Likely Spurious
The lab report itself notes that naproxen can cause spurious elevation of total bilirubin. This is a well-documented phenomenon where O-desmethylnaproxen (ODMN), a naproxen metabolite, interferes with certain bilirubin assays, particularly the Jendrassik and Grof method 2, 3. Critical supporting evidence:
- ALT (17 U/L) and AST (17 U/L) are completely normal - these are the most sensitive indicators of hepatocellular injury 1
- Albumin (3.7 g/dL) is normal - indicating preserved synthetic liver function
- Total protein (6.1 g/dL) is normal
- The bilirubin elevation is isolated without other signs of liver dysfunction
This pattern is inconsistent with true drug-induced liver injury (DILI), which typically presents with transaminase elevations 3× upper limit of normal or higher when clinically significant 1.
Alkaline Phosphatase (112 U/L) - Minimally Elevated
The ALP is only marginally above the upper limit (104 U/L). According to guidelines, abnormal liver tests should be interpreted in clinical context 4. This minimal elevation:
- Does not meet criteria for cholestatic injury (which requires more substantial elevation)
- Could represent bone origin rather than hepatic (check GGT to differentiate if concerned)
- Is not accompanied by elevated bilirubin from true cholestasis (the bilirubin is spurious)
Hemoglobin (13.4 g/dL) - Borderline Low
The hemoglobin is just below the reference range (13.5 g/dL). The FDA label specifically addresses this 1:
- NSAIDs including naproxen commonly cause mild anemia through fluid retention, occult GI blood loss, or effects on erythropoiesis
- The label recommends periodic hemoglobin monitoring for patients on long-term NSAID therapy
- Patients with hemoglobin ≤10 g/dL on long-term therapy require periodic monitoring 1
This patient's hemoglobin of 13.4 g/dL does not meet the threshold for heightened concern, but warrants awareness.
Management Algorithm
Immediate Actions
- Continue naproxen if clinically indicated and patient is asymptomatic - the laboratory abnormalities do not represent true hepatotoxicity
- Do NOT discontinue naproxen based solely on these labs - the bilirubin is artifactual and transaminases are normal
- Assess for symptoms of liver disease (nausea, fatigue, jaundice, right upper quadrant pain, pruritus) - if present, reconsider 1
- Assess for GI symptoms (epigastric pain, melena, hematemesis) given borderline hemoglobin 1
Follow-up Monitoring
If continuing naproxen:
- Repeat liver function tests (including GGT to clarify ALP source) in 4-8 weeks 4
- Repeat CBC in 4-8 weeks to monitor hemoglobin trend 1
- If transaminases rise to >3× upper limit of normal, discontinue naproxen immediately 1
- If hemoglobin continues to decline or patient develops anemia symptoms, evaluate for GI blood loss
If naproxen is discontinued for other reasons:
- Repeat bilirubin in 1-2 weeks - it should normalize as ODMN clears, confirming spurious elevation 2
When to Pursue Liver Workup
According to guidelines, pursue a standard liver aetiology screen if 4:
- Transaminases become elevated (>3× ULN)
- Patient develops symptoms of liver disease
- Bilirubin remains elevated after naproxen discontinuation
- ALP continues to rise
Standard workup would include: abdominal ultrasound, hepatitis B/C serology, autoimmune antibodies (AMA, ASMA, ANA), immunoglobulins, ferritin, and transferrin saturation 4.
Critical Pitfalls to Avoid
Do not misinterpret spurious hyperbilirubinemia as DILI - this leads to unnecessary drug discontinuation 2. The key distinguishing feature is normal transaminases.
Do not ignore the borderline hemoglobin - while not critically low, NSAIDs can cause occult GI bleeding that may worsen over time 1.
Do not over-investigate the minimal ALP elevation - in isolation with normal transaminases and albumin, this is not clinically significant 4.
Recognize that up to 15% of NSAID users have borderline liver test elevations that are transient and benign 1. True DILI with naproxen is rare but serious when it occurs 5, 6.
Iron Studies and Thyroid Function
The iron panel and thyroid function tests are all within normal limits and do not contribute to the bilirubin or hemoglobin findings. These require no intervention.